Equities Analysts Issue Forecasts for RNTX FY2026 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Investment analysts at HC Wainwright decreased their FY2026 EPS estimates for Rein Therapeutics in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($1.63) for the year, down from their previous estimate of ($0.80). The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.46) EPS and FY2029 earnings at ($1.22) EPS.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.12).

RNTX has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Wall Street Zen downgraded Rein Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. Finally, Citigroup downgraded Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Rein Therapeutics has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Trading Down 0.6%

Shares of NASDAQ:RNTX opened at $1.57 on Tuesday. The stock has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $1.30. The stock has a market capitalization of $44.02 million, a price-to-earnings ratio of -0.80 and a beta of 1.40. Rein Therapeutics has a 12-month low of $1.02 and a 12-month high of $2.40.

Hedge Funds Weigh In On Rein Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RNTX. Voss Capital LP raised its position in Rein Therapeutics by 86.0% in the 3rd quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after buying an additional 1,232,846 shares during the last quarter. Prosight Management LP raised its position in Rein Therapeutics by 32.7% in the 3rd quarter. Prosight Management LP now owns 567,898 shares of the company’s stock worth $650,000 after buying an additional 139,979 shares during the last quarter. Gagnon Securities LLC raised its position in Rein Therapeutics by 218.8% in the 3rd quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock worth $262,000 after buying an additional 156,947 shares during the last quarter. Gleason Group Inc. purchased a new position in Rein Therapeutics in the 3rd quarter worth about $26,000. Finally, Jane Street Group LLC purchased a new position in Rein Therapeutics in the 4th quarter worth about $72,000. 90.89% of the stock is currently owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.